Exenatide once weekly improved 24‐hour glucose control and reduced glycaemic variability in metformin‐treated participants with type 2 diabetes: a randomized, placebo‐controlled trial
Open Access
- 21 September 2016
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 19 (1) , 40-48
Abstract
Aim: To assess the effects of once‐weekly exenatide on 24‐hour glucose control and variability. Materials and methods: This double‐blind, placebo‐controlled trial randomized metformin‐treated adults with type 2 diabetes to once‐weekly exenatide 2.0 mg or placebo. Continuous glucose monitoring ( CGM ) was performed at baseline and weeks 4 and 10. The primary outcome was change in CGM ‐measured 24‐hour mean glucose level. Results: In the once‐weekly exenatide (n = 60) and placebo (n = 56) groups (modified intention‐to‐treat population), the baseline glycated haemoglobin ( HbA1c ) concentrations were 8.2% and 8.0%, respectively, and the fasting plasma glucose ( FPG ) concentration was 9.86 and 9.32 mmol/ L , respectively. Once‐weekly exenatide significantly (p < 0.001) reduced 24‐hour mean glucose level versus placebo (week 4, −1.44 vs −0.29 mmol/ L ; week 10, −1.71 vs −0.17 mmol/ L ), with consistent control throughout the week. Once‐weekly exenatide significantly reduced FPG and 2‐hour postprandial glucose ( PPG ) levels versus placebo at week 4 ( FPG , −1.65 vs −0.11 mmol/ L ; PPG , −1.79 vs −0.11 mmol/ L ) and week 10 ( FPG , −2.32 vs −0.28 mmol/ L ; PPG , −2.46 vs −0.33 mmol/ L ). At week 10, once‐weekly exenatide reduced the mean amplitude of glucose excursions ( MAGE ; −0.84 vs 0.16 mmol/ L ) and standard deviation (s.d.) of mean glucose (−0.35 vs 0.04 mmol/ L ). By week 10, once‐weekly exenatide‐treated participants spent more time in euglycaemia (once‐weekly exenatide, 77% vs placebo, 58%), less time in hyperglycaemia (22% vs 42%), and a similar time in hypoglycaemia (0.7% vs 0.3%). Common adverse events were injection‐site nodule (once‐weekly exenatide, 10.0% vs placebo, 0.0%), urinary tract infection (6.7% vs 8.9%) and nausea (6.7% vs 0.0%). Conclusions: In metformin‐treated participants with type 2 diabetes, once‐weekly exenatide significantly improved daily glucose control and reduced glycaemic variability at weeks 4 and 10, as shown by reductions in 24‐hour glucose, FPG and PPG levels, MAGE and s.d., and increased time spent in euglycaemia.Keywords
Funding Information
- AstraZeneca
This publication has 29 references indexed in Scilit:
- Efficacy, Safety, and Tolerability of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus: An Integrated Analysis of the DURATION TrialsPostgraduate Medicine, 2013
- GLP ‐1 receptor activated insulin secretion from pancreatic β‐cells: mechanism and glucose dependenceDiabetes, Obesity and Metabolism, 2012
- Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP ‐1 receptor agonism in patients with type 2 diabetesDiabetes, Obesity and Metabolism, 2012
- Encapsulation of Exenatide in Poly-( d,l -Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 DiabetesDiabetes Technology & Therapeutics, 2011
- Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple DosingClinical Pharmacokinetics, 2011
- Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literatureDiabetes, Obesity and Metabolism, 2010
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyThe Lancet, 2008
- Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 DiabetesDiabetes Care, 2007
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Relationship between lactate dehydrogenase and myeloperoxidase levels in human gingival crevicular fluid and clinical and microbial measurementsJournal of Clinical Periodontology, 1988